Advertisement

Reactions Weekly

, Volume 1153, Issue 1, pp 4–4 | Cite as

Three new cases of immune thrombocytopenic purpura (ITP) were diagnosed in patients who had received alemtuzumab in a phase II trial, CAMMS223

Clinical study
  • 9 Downloads

Keywords

Public Health Multiple Sclerosis Corticosteroid Platelet Count American Academy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

REFERENCE

  1. 1.
    Sullivan H, CAMMS223 Study Group.ITP following treatment of multiple sclerosis patients with alemtuzumab in CAMMS223: case reports and risk management plan implementation. Neurology 68 (Suppl. 1): 206, No. 12, 20 Mar 2007Google Scholar

Copyright information

© Adis International limited or Adis Data Information BV 2007

Personalised recommendations